An Indian Multi-centric Phase IV Study to Assess the Safety of Crizanlizumab in Sickle Cell Disease Patients
Clinical trial NCT04662931 · COMPLETED
Trial details
- NCT number
- NCT04662931
- Sponsor
- Novartis Pharmaceuticals
- Status
- COMPLETED
- Phase
- Phase 4
- Study type
- INTERVENTIONAL
- Start date
- 2021-07-14
- Primary completion
- 2024-02-14
- Enrollment
- 140
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.